Targeted Regulatory T Cells to Treat SLE
Abstract
Lupus manifests as multi-organ dysfunction. It is caused by a misdirected immune response that targets the components within a person’s own cells. Using innovative patented approaches that exploit the latest in genetic engineering, this project will develop a cell-based therapy that specifically inhibits the misdirected immune response. This novel therapy will significantly improve the lives of patients living with lupus. Specifically, this treatment is designed for patients at high risk of developing kidney failure. It will prevent the progression of disease and mean that thousands of patients will not have to be on dialysis or require a kidney transplant to survive. We have already shown in proof-of-concept experiments that this new cell-based therapy works, and we are now seeking funding to perform experiments that will enable the translation of this therapy into clinical trials. Following the completion of this project, clinical trials will commence within a few years.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210256
Entities
People
- Joshua D. Ooi
Organizations
- Monash University
- United States Army